Search results for: 'Digitalization of Pharma Value Chain'

The value-based care (VBC) model aims to offer better outcomes and care quality to patients cost-effectively. Multiple stakeholders, including payers, healthcare providers, and medical technology (medtech) players, can share the revenue risk and incentive for providing better value. The United States is a pioneer in VBC adoption, followed by countr...

According to the Centers for Medicare and Medicaid Services (CMS), value-based care (VBC) programs reward healthcare providers with incentive payments for the quality of care they provide Medicare patients. These programs are part of its larger CMS quality strategy to reform healthcare delivery and payment. Value-based programs support 3 aims: b...

21 Jan 2025  |  Global  |  Technology Research

Technologies Enabling Resilient Pharmaceutical Supply Chains

AI-enabled Technologies are Transforming the Pharmaceutical Supply Chain Network

Infographics

×

This study aims to review emerging, transformative technology solutions that redesign pharmaceutical supply chain processes and introduce increased resilience, transparency, and responsiveness into the model. The study answers the following questions: What are some new challenges big pharma's supply chains must address today? How can emerging tec...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

The research service primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights into the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalization of key processes ac...

Frost & Sullivan defines digital health as data application for healthcare delivery using computational and telecommunication technologies to support business process workflow, clinical workflow, and patient data management. Digital health aims to achieve better patient outcomes while improving efficiency and containing costs through provider and p...

This research study evaluates the evolving global digital therapeutics (DTx) ecosystem, with a focused analysis on Cognitive DTx and Metabolic DTx. The study examines the transition of DTx from emerging digital health tools toward clinically validated, interoperable, and scalable therapeutic platforms integrated within broader healthcare ecosystems...